Kerstin Hellwig (Ruhr University Bochum, Bochum, Germany) discusses family planning considerations in multiple sclerosis. This Review is published in the April issue of The Lancet Neurology.

Geraldine Dawson (Duke University School of Medicine, NC, USA ) discusses the latest advances and ongoing challenges in prediction of autism during infancy. This Review is published in the March issue of The Lancet Neurology.

Read the full article:
Prediction of autism in infants: progress and challenges

Ellisiv Mathiesen (The University of Tromsø – the Arctic University of Norway, Tromsø, Norway) discusses the findings of the TWIST trial, which investigated the use of tenecteplase for patients with wake-up stroke who were selected for treatment by non-contrast CT. This Fast-track Article is published in the February issue of The Lancet Neurology.

Read the full article:
Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST)

Beau Ances (Washington University in St Louis, MO, USA) discusses recent research on amyloid biomarkers in people with genetic forms of Alzheimer’s disease; his Article is published in the January issue of The Lancet Neurology.

Read the full article:
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease

Axel Petzold (National Hospital for Neurology and Neurosurgery and Moorfields Eye Hospital, London, UK, and Amsterdam University Medical Center, Amsterdam, Netherlands) discusses a Position Paper, published in the December issue of The Lancet Neurology, which sets out new criteria for the diagnosis and classification of optic neuritis.

Read the Position Paper:
Diagnosis and classification of optic neuritis

Maeike Zijlmans (University Medical Center Utrecht, Utrecht, Netherlands) discusses recent research on tailoring of epilepsy surgery with biomarkers on intraoperative electrocorticography, and describes some of the challenges of this technique and what the future steps are for the field; the Article is published in the November issue of The Lancet Neurology.

Jerome Siegel (University of California, Los Angeles, CA, USA) discusses sleep research in hunter-gatherer populations and what we can learn from the sleep habits of various species; his Review is published in the October issue of The Lancet Neurology, which is the fourth paper in The Lancet’s Series on sleep and sleep disorders. 

Laurent Servais and Dora Markati (both from the University of Oxford, UK) discuss emerging therapies for Duchenne muscular dystrophy; their Review is published in the September issue of The Lancet Neurology.

Read the full Review:
Emerging therapies for Duchenne muscular dystrophy

Andreas Charidimou (Massachusetts General Hospital, Boston, MA, USA) discusses an international collaborative study that presents new Boston criteria for diagnosis of cerebral amyloid angiopathy; the Article is published in the August issue of The Lancet Neurology.

Read the full article:
The Boston criteria version 2.0 for cerebral amyloid angiopathy

Sarah Tabrizi (UCL Queen Square Institute of Neurology, London, UK) and Cristina Sampaio (CHDI Foundation, Princeton, NJ, USA) discuss two papers on Huntington’s disease published in the July issue of The Lancet Neurology: a Position Paper outlining a new classification of the disease, called the Huntington’s Disease Integrated Staging System, and a Personal View on potential disease-modifying therapies.

Mark Hallett (National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA) discusses his Review, published in the June issue of The Lancet Neurology, on functional neurological disorder, and talks about new subtypes of this disorder, diagnostic challenges, and how education is important.

Read the full article:
Functional neurological disorder: new subtypes and shared mechanisms

Eva Feldman (University of Michigan, Ann Arbor, USA) discusses the latest advances in the genetics, risk factors, pathophysiology, therapeutic development, and the diagnosis and prognosis of amyotrophic lateral sclerosis; the Series is published in the May issue of The Lancet Neurology.

Estrella Morenas-Rodriguez and Christian Haass (German Centre for Neurodegenerative Diseases, Munich, Germany) discuss their recent research, published in the April issue of The Lancet Neurology, on soluble TREM2 and its association with Alzheimer’s disease biomarkers and cognition.

John Collinge (MRC Prion Unit, University College London, London, UK) discusses a first-in-human treatment programme to give PRN100, an anti-prion-protein monoclonal antibody, to patients with Creutzfeldt–Jakob disease; the report is published in the April issue of The Lancet Neurology.

Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.

Read the full article:
Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL)

Giuseppe Citerio (University of Milano-Bicocca, Milan, Italy) discusses the implications of a study from the CENTER-TBI project of the effect of frailty on 6-month outcome after traumatic brain injury, which is published in the February issue of The Lancet Neurology. 

Alberto Costa (Case Western Reserve University, Cleveland, OH, USA) discusses his study on the use of memantine in adolescents and young adults with Down syndrome, which is published in the January issue of The Lancet Neurology.

Read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00369-0/fulltext

Olivier Rascol (Toulouse University, France) discusses the uses of amantadine in the treatment of patients with movement disorders, which are the focus of his Personal View in the December issue of The Lancet Neurology.

Read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00249-0/fulltext

Antonio Uccelli (University of Genoa) discusses his research, published in the November issue of The Lancet Neurology, on the therapeutic use of mesenchymal stem cells for multiple sclerosis.

Read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00301-X/fulltext

Priya Palta (Columbia University, New York) explains the importance of blood pressure control in the prevention of cognitive decline. Her Review, published in the October issue of The Lancet Neurology, provides an update of the mounting evidence that links hypertension with dementia risk.

Read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00248-9/fulltext

Adam Boxer (University of California, San Francisco) discusses his research, published in August issue of The Lancet Neurology, on diagnostic performance of tau biomarkers in neurodegenerative diseases.

Read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00214-3/fulltext

Irene Cortese (National Institute of Neurological Disorders and Stroke) discusses the difficulties of designing clinical trials in progressive multifocal leukoencephalopathy and talks about a pilot study of virus-specific T cells for treatment of this population, published in the August issue of The Lancet Neurology.

Read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00174-5/fulltext

Doug Turnbull (University of Newcastle) discusses mitochondrial diseases in adults, which are reviewed in the July issue of The Lancet Neurology, and explains how important these diseases are for neurologists.

Read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00098-3/fulltext

Geert Jan Biessels (University Medical Centre Utrecht) discusses his research, published in our June issue, on using strategic infarct locations to predict post-stroke cognitive impairment.

Read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00060-0/fulltext

Henk-Jan Westeneng  discusses his new work on the causal effects of pre-symptomatic lifestyle on ALS.

Read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00042-9/fulltext